{
  "abstract": "Background: Maternal embryonic leucine zipper kinase (MELK) is a cell cycle-regulated serine/threonine kinase frequently overexpressed in human malignancies, and represents a promising anticancer drug target. Discovery of structurally novel, highly selective MELK inhibitors remains an unmet need. Methods: In the study, we implemented an integrated computational pipeline combining four machine learning regressors (Random Forest, Gradient Boosting, XGBoost, LightGBM), hierarchical Glide docking (HTVS to SP to XP), MM/GBSA rescoring, ADMET prediction, and 100 ns molecular dynamics simulations to screen a ~15.58 million-compound commercial library, yielding 12 prioritized candidates. Three commercially available compounds (CPD4, CPD6, CPD10) were evaluated in an antiproliferative panel. Results: CPD6 was identified as the most active hit, with IC50 values of 1.44 μM in MDA-MB-468 and 1.66 μM in H1299, modestly exceeding the reference compound MELK-8a under the same assay conditions (2.48 and 2.51 μM, respectively). Cellular thermal shift assay in cell lysates provided biochemical evidence of MELK engagement, and 100 ns molecular dynamics simulations supported a computationally predicted binding mode in the MELK kinase domain. Additional substrate phosphorylation and MELK overexpression rescue assays further supported MELK-dependent inhibitory activity. Colony formation, EdU incorporation, and cell cycle analyses demonstrated dose-dependent antiproliferative effects and G2/M arrest, with concomitant downregulation of CDC25C, CDK1, and Cyclin B1. Discussion: CPD6 is a structurally novel MELK lead distinct from reported inhibitors. While our data support MELK target engagement, kinome selectivity profiling remains required, and this ML pipeline demonstrates the utility of AI-driven large-scale anticancer lead screening. Conclusions: Using the integrated machine-learning virtual screening pipeline established in this work, we identified CPD6 as a structurally novel MELK-targeted lead that engages MELK, induces G2/M arrest, and exerts low-micromolar antiproliferative activity in triple-negative breast cancer and lung adenocarcinoma models.",
  "abstract_shown": true,
  "affiliations": [
    "Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Druggability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China",
    "School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 117004, China",
    "School of Pharmacy, Henan University, Kaifeng 475004, China",
    "Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 12,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Wanxin Cao"
    },
    {
      "affs": [
        0
      ],
      "name": "Bin Jiang"
    },
    {
      "affs": [
        0
      ],
      "name": "Xiangyin Chi"
    },
    {
      "affs": [
        0
      ],
      "name": "Wan Li"
    },
    {
      "affs": [
        0
      ],
      "name": "Hong Yang"
    },
    {
      "affs": [
        1
      ],
      "name": "Xiaoxue Li"
    },
    {
      "affs": [
        2
      ],
      "name": "Yuxuan Zhao"
    },
    {
      "affs": [
        0
      ],
      "name": "Xu Zhang"
    },
    {
      "affs": [
        3
      ],
      "name": "Rui Meng"
    },
    {
      "affs": [
        0
      ],
      "name": "Yanyu Cang"
    },
    {
      "affs": [
        0
      ],
      "name": "Guanhua Du"
    },
    {
      "affs": [
        0
      ],
      "name": "Jinhua Wang",
      "orcid": "0000-0001-8367-0787"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8n9jzw30yvjen.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18203336",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702308/?tool=EBI",
  "id": "8n9jzw30yvjen",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://www.mdpi.com/2072-6694/18/20/3336",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "1703|Computational Drug Discovery Methods"
    ]
  ],
  "openalex": "W7221966920",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702308/pdf/?tool=EBI",
  "pmcid": "PMC13702308",
  "pmid": null,
  "published": "2026-10-01",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/8n9jzw30yvjen.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:58Z",
      "native_id": "10.3390/cancers18203336",
      "source": "crossref",
      "url": "https://www.mdpi.com/2072-6694/18/20/3336"
    },
    {
      "first_seen": "2026-10-30T12:21:31Z",
      "native_id": "PMC:PMC13702308",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13702308"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2072-6694",
      "subfield": "oncology"
    }
  ],
  "title": "Machine Learning-Guided Virtual Screening Identifies a Novel MELK-Targeted Antiproliferative Lead Compound with G2/M Arrest Activity in Triple-Negative Breast Cancer and Lung Adenocarcinoma Cells",
  "title_text": "Machine Learning-Guided Virtual Screening Identifies a Novel MELK-Targeted Antiproliferative Lead Compound with G2/M Arrest Activity in Triple-Negative Breast Cancer and Lung Adenocarcinoma Cells",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:31Z",
  "url": "https://research.draconitic.com/paper/8n9jzw30yvjen",
  "venue": "Cancers",
  "versions": []
}